Founded in 2019, AaviGen GmbH is a pre-clinical stage biotechnology company specializing in the development of transformative gene therapy medicinal products (GTMPs) for genetic and acquired cardiovascular and cardiopulmonary diseases. By leveraging a proprietary portfolio of genetically-engineered heart-specific Adeno-Associated Viruses (AAVs) to deliver therapeutic genes directly to the diseased heart cells via a single intravenous injection, AaviGen’s mission is to advance safe and effective precision GTMPs for heart-related ailments. Integrating cutting-edge technologies with the interdisciplinary expertise of its founders – spanning clinical cardiology, virology and genetic vector engineering, GTMP development, health economics and regulatory affairs – AaviGen strives to address the unmet needs of millions of patients worldwide with its scalable vector platform and therapeutic pipeline, ultimately reshaping the clinical landscape of cardiovascular care.